4506 — Sumitomo Pharma Share News
0.000.00%
Last trade - 00:00- ¥826bn
- ¥902bn
- ¥453bn
Japan's Nikkei slips as post-earnings and election momentum fade
Japan's Nikkei slips as SoftBank drags; post-election momentum fades
Nikkei dips as soft data, post-election lull cap moves
Table: Sumitomo Pharma -9-MTH group results (IFRS)
Table: Sumitomo Pharma 6-MTH group results (IFRS)
Shares of Asian drugmakers drop after Trump threatens tariffs (updated)
Focus: Parkinson's disease at forefront of Bayer bet on cell and gene therapies
Bayer moves Parkinson's cell therapy into Phase III trial
Submission Of Application Of Manufacturing And Marketing Authorization For Ips Cell-Derived Dopaminergic Neural Progenitor Cells In Japan
Table: Sumitomo Pharma -Q1 group results (IFRS)
Brief: Sumitomo Pharma America Says Nuvisertib (TP-3654) Gets EMA Orphan Drug Status For Treating Myelofibrosis
Notice Of Assignment Of Assets For Key Products In The U.S. Within Sumitomo Pharma Group
Japan's Nikkei retreats from 4-month high as US-Iran tensions weigh
Japan's Nikkei retreats from 4-month high as threat of US involvement in Iran conflict looms
Japanese shares rise for third day on tech optimism, JGB support
Brief: Knight Therapeutics And Sumitomo Pharma Enter Into Exclusive Licensing Agreements To Commercialize Sumitomo’S Canadian Portfolio
Japan's Nikkei surges as trade optimism lifts tech; Toyota Industries plunges
Table: Sumitomo Pharma -2024/25 group results (IFRS)
Table: Sumitomo Pharma -2024/25 parent results